Cequent Pharmaceuticals Inc.
Peter Parker, Cambridge, MA, US
Cequent is pioneering the development of novel therapeutics to prevent and treat a wide range of human diseases – from inflammatory diseases to cancer – based on the company’s proprietary technology, TransKingdom RNA interference (tkRNAi) which uses non-pathogenic bacteria as an engine to produce and deliver RNAi directly into cells. Cequent’s first products, now in pre-clinical development, are drug candidates targeting colon-cancer prevention and inflammatory bowel disease.
Dr. Lauren Silverman (Board Seat)